SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma

Istituto Clinico Humanitas37 enrolled

Overview

In this study the investigators treat PM oligometastatic patients with SBRT. Our objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung metastases from STS.

The investigators started to treat PM oligometastatic patients with Stereotactic Body Radiotherapy. The investigators objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung metastases from soft-tissue sarcomas. Overall and disease free survival will be evaluated as secondary endpoints.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastasis From Malignant Tumor of Soft Tissues

Interventions

Lung metastasis from soft-tissue sarcomaRADIATION

Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 anni -85 years * PS according to ECOG 0-2 * Histopathologically confirmation of soft tissue sarcoma * Metastatic lung lesion less than 4 * Controlled primary tumor and other metastatic lesions * Metastatic lesion less than 5 such as the definition of oligometastatic patients * Written informed consent * Contraindication to surgical resection * Estimated survival ≥ 3 months * Absence of progressive disease longer than 6 months * No chemotherapy was given for at least 3 months after SBRT * Maximum diameter ≤ 5 cm Exclusion Criteria: * Prior thorax radiation therapy * Age \> 85 years * PS according to ECOG \>2 * Pregnant women * Maximum diameter ≥ 5.1 cm * Total volume of lung lesion greater than 1/3 of the whole pulmonary parenchima

Locations (1)

Istituto Clinico Humanitas

Rozzano, MI, Milan, Italy

Outcomes

Primary Outcomes

Local control of treated lesions

Evaluation of proportion of patients free from progression from starting radiotherapy

Time frame: 12 months

Secondary Outcomes

Overall survival of treated patients

Evaluation of proportion of patients alive

Time frame: 4 years

Disease free survival of treated patients

Evaluation of proportion of patients alive and free from progression

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.